請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72017
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蔡幸真(Hsing-Chen Tsai) | |
dc.contributor.author | Giovanni Audrey Oswita | en |
dc.contributor.author | 胡斯萍 | zh_TW |
dc.date.accessioned | 2021-06-17T06:19:18Z | - |
dc.date.available | 2021-08-30 | |
dc.date.copyright | 2018-08-30 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-08-20 | |
dc.identifier.citation | 1. Pliml, J. & Šorm, F. Synthesis of a 2-deoxy-D-ribofuranosyl-5-azacytosine. Collection of Czechoslovak chemical communications 29, 2576–2578 (1964).
2. Sorm, F. & Veselý, J. Effect of 5-aza-2’-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 15, 339–343 (1968). 3. Groeningen, C. J. van, Leyva, A., O’Brien, A. M. P., Gall, H. E. & Pinedo, H. M. Phase I and Pharmacokinetic Study of 5-Aza-2′-deoxycytidine (NSC 127716) in Cancer Patients. Cancer Res 46, 4831–4836 (1986). 4. FDA Approves Five-Day Dosing Regimen for Dacogen (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS). Drugs.com Available at: https://www.drugs.com/newdrugs/fda-approves-five-day-dosing-regimen-dacogen-decitabine-offering-new-outpatient-dosing-option-2042.html. (Accessed: 30th May 2018) 5. Bohl, S. R., Bullinger, L. & Rücker, F. G. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia. Expert Review of Hematology 11, 361–371 (2018). 6. Garcia-Manero, G. et al. Successful Emulation of IV Decitabine Pharmacokinetics with an Oral Fixed-Dose Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine, in Subjects with Myelodysplastic Syndromes (MDS): Final Data of Phase 1 Study. Blood 128, 114–114 (2016). 7. Roboz, G. J. et al. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer 124, 325–334 8. He, P.-F. et al. Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. Oncotarget 5, (2017). 9. Adult Acute Myeloid Leukemia Treatment. National Cancer Institute Available at: https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq#section/all. (Accessed: 12th May 2018) 10. Wang, H. et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet 388, 1459–1544 (2016). 11. Song, X. et al. Incidence, Survival, and Risk Factors for Adults with Acute Myeloid Leukemia Not Otherwise Specified and Acute Myeloid Leukemia with Recurrent Genetic Abnormalities: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database, 2001–2013. AHA 139, 115–127 (2018). 12. Wass, M., Hitz, F., Schaffrath, J., Müller-Tidow, C. & Müller, L. P. Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia. PLoS One 11, (2016). 13. Pogoda, J. M., Preston-Martin, S., Nichols, P. W. & Ross, R. K. Smoking and Risk of Acute Myeloid Leukemia: Results from a Los Angeles County Case-Control Study. Am J Epidemiol 155, 546–553 (2002). 14. Ugai, T. et al. Smoking and subsequent risk of leukemia in Japan: The Japan Public Health Center-based Prospective Study. J Epidemiol 27, 305–310 (2017). 15. Fircanis, S., Merriam, P., Khan, N. & Castillo, J. J. The relation between cigarette smoking and risk of acute myeloid leukemia: An updated meta-analysis of epidemiological studies. American Journal of Hematology 89, E125–E132 16. Bennett, J. M. et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann. Intern. Med. 103, 620–625 (1985). 17. Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405 (2016). 18. Dupont, C., Armant, D. R. & Brenner, C. A. Epigenetics: Definition, Mechanisms and Clinical Perspective. Semin Reprod Med 27, 351–357 (2009). 19. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6–21 (2002). 20. Benevolenskaya, E. V. Histone H3K4 demethylases are essential in development and differentiationThis paper is one of a selection of papers published in this Special Issue, entitled 28th International West Coast Chromatin and Chromosome Conference, and has undergone the Journal’s usual peer review process. Biochem. Cell Biol. 85, 435–443 (2007). 21. Janssen, K. A., Sidoli, S. & Garcia, B. A. Recent Achievements in Characterizing the Histone Code and Approaches to Integrating Epigenomics and Systems Biology. Methods Enzymol 586, 359–378 (2017). 22. Hong, L., Schroth, G. P., Matthews, H. R., Yau, P. & Bradbury, E. M. Studies of the DNA binding properties of histone H4 amino terminus. Thermal denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 ‘tail’ to DNA. J. Biol. Chem. 268, 305–314 (1993). 23. Morinière, J. et al. Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 461, 664–668 (2009). 24. Cosgrove, M. S., Boeke, J. D. & Wolberger, C. Regulated nucleosome mobility and the histone code. Nature Structural & Molecular Biology 11, 1037–1043 (2004). 25. Prakash, K. A Condensed History of Chromatin Research. in Chromatin Architecture 1–24 (Springer, Cham, 2017). doi:10.1007/978-3-319-52183-1_1 26. Blancafort, P., Jin, J. & Frye, S. Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules. Mol. Pharmacol. 83, 563–576 (2013). 27. Giorgio, C., Dell’Aversana, C. & Altucci, L. Chapter 27 - Epigenetics in Acute Myeloid Leukemia. in Medical Epigenetics (ed. Tollefsbol, T. O.) 483–498 (Academic Press, 2016). doi:10.1016/B978-0-12-803239-8.00027-2 28. Prakash, K. & Fournier, D. Deciphering the histone code to build the genome structure. bioRxiv 217190 (2017). doi:10.1101/217190 29. Pei, H. et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 470, 124–128 (2011). 30. Kuo, A. J. et al. The BAH domain of ORC1 links H4K20me2 to DNA replication licensing and Meier-Gorlin syndrome. Nature 484, 115–119 (2012). 31. Blackledge, N. P. et al. Variant PRC1 complex-dependent H2A ubiquitylation drives PRC2 recruitment and polycomb domain formation. Cell 157, 1445–1459 (2014). 32. Cooper, S. et al. Targeting polycomb to pericentric heterochromatin in embryonic stem cells reveals a role for H2AK119u1 in PRC2 recruitment. Cell Rep 7, 1456–1470 (2014). 33. Cedar, H. & Bergman, Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 10, 295–304 (2009). 34. Lunyak, V. V. et al. Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science 298, 1747–1752 (2002). 35. Fuks, F. et al. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 278, 4035–4040 (2003). 36. Prasad, P., Lennartsson, A. & Ekwall, K. The Roles of SNF2/SWI2 Nucleosome Remodeling Enzymes in Blood Cell Differentiation and Leukemia. Biomed Res Int 2015, (2015). 37. Papaemmanuil, E. et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. New England Journal of Medicine 374, 2209–2221 (2016). 38. Larizza, L., Magnani, I. & Beghini, A. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leukemia & Lymphoma 46, 247–255 (2005). 39. Tsai, H.-C. et al. Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells. Cancer Cell 21, 430–446 (2012). 40. Ong, S.-E. et al. Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics. Mol Cell Proteomics 1, 376–386 (2002). 41. Buchi, F. et al. Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. Leuk. Res. 36, 607–618 (2012). 42. Zhang, C. et al. Quantitative proteomic analysis of histone modifications in decitabine sensitive and resistant leukemia cell lines. Clin Proteomics 13, (2016). 43. Zhou, F. et al. AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia. Nat Cell Biol 19, 844–855 (2017). 44. Schreiber, E., Matthias, P., Müller, M. M. & Schaffner, W. Rapid detection of octamer binding proteins with ‘mini extracts’, prepared from a small number of cells. Nucleic Acids Res 17, 6419–6419 (1989). 45. Shannon, P. et al. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res. 13, 2498–2504 (2003). 46. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44–57 (2009). 47. Maere, S., Heymans, K. & Kuiper, M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 21, 3448–3449 (2005). 48. Szklarczyk, D. et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res 45, D362–D368 (2017). 49. Bader, G. D. & Hogue, C. W. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 4, 2 (2003). 50. Hwang, S.-I. et al. Systematic characterization of nuclear proteome during apoptosis: a quantitative proteomic study by differential extraction and stable isotope labeling. Mol. Cell Proteomics 5, 1131–1145 (2006). 51. Cashen, A. F., Shah, A. K., Todt, L., Fisher, N. & DiPersio, J. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 61, 759–766 (2008). 52. Stresemann, C., Brueckner, B., Musch, T., Stopper, H. & Lyko, F. Functional Diversity of DNA Methyltransferase Inhibitors in Human Cancer Cell Lines. Cancer Res 66, 2794–2800 (2006). 53. Zhang, L. et al. Histone H4 N-Terminal Acetylation in Kasumi-1 Cells Treated with Depsipeptide Determined by Acetic Acid–Urea olyacrylamide Gel Electrophoresis, Amino Acid Coded Mass Tagging, and Mass Spectrometry. J Proteome Res 6, 81–88 (2007). 54. Graumann, J. et al. Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Proteome Quantitation of Mouse Embryonic Stem Cells to a Depth of 5,111 Proteins. Mol Cell Proteomics 7, 672–683 (2008). 55. Mauvoisin, D. et al. Circadian clock-dependent and -independent rhythmic proteomes implement distinct diurnal functions in mouse liver. PNAS 111, 167–172 (2014). 56. Wang, J. et al. Nuclear Proteomics Uncovers Diurnal Regulatory Landscapes in Mouse Liver. Cell Metab 25, 102–117 (2017). 57. Sarkar, P. et al. Identification of Epigenetic Factor Proteins Expressed in Human Embryonic Stem Cell-Derived Trophoblasts and in Human Placental Trophoblasts. J. Proteome Res. 15, 2433–2444 (2016). 58. Agrawal-Singh, S. et al. Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood 119, 2346–2357 (2012). 59. Zhang, F., Dai, X. & Wang, Y. 5-Aza-2′-deoxycytidine Induced Growth Inhibition of Leukemia Cells through Modulating Endogenous Cholesterol Biosynthesis. Mol Cell Proteomics 11, M111.016915 (2012). 60. Zhou, L. et al. Methylation-associated silencing of BASP1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia. Experimental & Molecular Medicine 50, 44 (2018). 61. Du, Z. et al. DNMT1 Stability Is Regulated by Proteins Coordinating Deubiquitination and Acetylation-Driven Ubiquitination. Sci. Signal. 3, ra80–ra80 (2010). 62. Zhu, H. et al. Lsh is involved in de novo methylation of DNA. EMBO J. 25, 335–345 (2006). 63. Myant, K. & Stancheva, I. LSH Cooperates with DNA Methyltransferases To Repress Transcription. Mol Cell Biol 28, 215–226 (2008). 64. Pan, C., Kumar, C., Bohl, S., Klingmueller, U. & Mann, M. Comparative Proteomic Phenotyping of Cell Lines and Primary Cells to Assess Preservation of Cell Type-specific Functions. Mol Cell Proteomics 8, 443–450 (2009). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72017 | - |
dc.description.abstract | 急性骨髓性白血病(AML)是一種白血球細胞的侵襲性癌症,好發於六十歲以上的長者 。這些病患們常同時罹患其他疾病,故不適合進行較激烈的化學治療或幹細胞移植手術。地西他濱(decitabine)是一種DNA去甲基化藥物,許多臨床試驗已證實這個藥物對年長之急性骨髓性白血病病患具有療效,且多數病患對於此低劑量之表觀遺傳治療具有良好的耐受性,只有輕微的不良反應。我們之前的研究顯示,血癌細胞株和人體初代白血病細胞對於低劑量地西他濱之抑癌效果具有“記憶”效應,這些作用伴隨著全基因體啟動子DNA甲基化的持續降低與許多核心訊息傳導路徑中基因的重新表達。此外,過去研究亦發現地西他濱除了能把DNA去甲基化,還能夠改變全基因體染色質結構和組蛋白修飾,而此染色質變化是因地西他濱對染色質修飾蛋白的直接調節作用或是對基因表達變化的間接反應目前尚不清楚 。因此,本篇研究目的是使用SILAC(以穩定同位素標記之氨基酸進行細胞培養)定量蛋白體學,研究地西他濱治療白血病細胞後染色質修飾蛋白的動態變化。首先,我們使用低劑量的地西他濱處理Kasumi-1白血病細胞株72小時,然後讓細胞株於無藥物之培養基中生長4天,使藥物充份發揮其表觀遺傳效應。接著,在地西他濱處理後的幾個時間點收取細胞以進行全細胞及核蛋白質體學分析。全細胞蛋白質體學發現地西他濱可影響許多細胞分子功能,如細胞凋亡,溶酶體,細胞骨架,蛋白水解等,這與我們過去研究的轉錄體結果一致。接著,我們進行核蛋白質體的分析,因為大多數已知的染色質修飾蛋白位於細胞核內。
為了更深入了解地西他濱處理後不同時間點之蛋白質體動態變化,本研究使用了數種不同的蛋白質體分析軟體來做進一步的分析,如MCODE-蛋白質網絡群集分析與分量回歸分析。結果顯示,在地西他濱連續處理 72 小時後,核蛋白體中與染色質修飾, 染色質組裝及核小體組裝相關的蛋白有顯著增加的現象,而在地西他濱處理後的第八天 (即地西他濱連續處理 72小時後,移除藥物再培養四天),有顯著變化之蛋白體明顯擴展至各種不同細胞功能網絡,例如對細胞激素的反應,干擾素訊息傳遞,氧化還原代謝反應,細胞有絲分裂等。核蛋白質體分析亦對用藥前後之表觀遺傳相關蛋白變化提供了較佳之質譜鑑定與分辨率。我們發現,白血病細胞經地西他濱處理後,大多數的組蛋白乙醯轉移酶,去乙醯酶及其輔因子表達降低。此外,本研究還觀察到大約30種染色質重塑蛋白於用藥前後有明顯變化,顯示在地西他濱處理後染色質發生了重大變化。總而言之,我的研究深入探討了地西他濱對急性白血病細胞株的表觀遺傳蛋白及其細胞內網路的時序性調控。 | zh_TW |
dc.description.abstract | Acute myeloid leukemia (AML) is an aggressive type of white blood cell cancer with most patients being beyond 60 years of age. These elderly patients are often present with various comorbidities that make them unsuitable for harsh conventional chemotherapy or curative stem cell transplantation. Decitabine (DAC), a DNA demethylating agent, was found to confer some efficacy to this group of patients in clinical trials. The low-dose epigenetic regimen is generally well-tolerated with mild adverse effects. Previously, our study had shown that DAC at clinically-relevant low doses induces ‘memory-like’ antitumor response in AML cell lines and primary human AML cells. These effects were accompanied by sustained decreases in genome-wide promoter DNA methylation and re-expression of genes in many core signaling pathways. Moreover, we found that DAC was able to alter genome-wide chromatin structure and histone modifications in addition to DNA demethylation. Nevertheless, it remains unclear whether DAC-induced chromatin changes are the results of direct regulatory effects of DAC on chromatin modifiers or indirect responses to global gene expression changes. Thus, the aim of this study is to characterize the dynamic changes of chromatin modifiers in leukemia cells following low-dose DAC treatment using stable isotope labeling with amino acid in cell culture (SILAC)-based quantitative proteomics.
Firstly, Kasumi-1 AML cell line was treated with DAC at a clinically-relevant dose for 3 days (Day 4) followed by a DAC-free growth for 4 days (Day 8), allowing the drug to fully exert its epigenetic effects. Next, whole cell lysate and nuclear proteins were extracted on Day 4 and Day 8, then analyzed with proteomics method. With the whole cell lysate, we identified major biological processes and cell compartment annotation mediated by DAC, such as apoptosis, lysosome, cytoskeleton, proteolysis, etc, which was in consistent with our previous transcriptomic data. Subsequently, we focused on nuclear proteomics since most of the known chromatin modifiers are localized in the nucleus. To gain insight into the dynamic proteomic changes over a time course following DAC treatment, we employed MCODE-protein network clustering bioinformatics analysis. The result showed that on Day 4 following DAC-treatment, nuclear-isolated proteins showed enrichment of pathways related to chromatin modification, chromatin organization and nucleosome assembly. On day 8, the modulated networks shifted to additional pathways such as response to cytokine, type I interferon signaling, oxidation-reduction metabolic process, mitotic cell cycle, transcription elongation, etc. The result of nuclear-isolated proteins also revealed better mass spectrometry identification and resolution on epigenetic-related proteins. Interestingly, in epigenetic proteins, we observed the downregulation of histone acetyl-transferases and deacetylases. On the other hand, more than 30 chromatin remodeling proteins were also differentially expressed, indicating that major changes happened at the chromatin level post-DAC treatment. Furthermore, one of the chromatin modifiers, lymphoid-specific helicase (HELLS) was upregulated on Day 4 and downregulated on Day 8 following DAC treatment which occurred inversely to DNMT1 levels. The differential expression of HELLS was also validated by immunoblot analysis. We will further investigate the role of HELLS on the anti-tumor effect of DAC-treatment in AML cell line. Hence, our result shed some light on the previously unclear modulation of cellular and epigenetic pathways by DAC in a human AML cell line over the time course of DAC treatment. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T06:19:18Z (GMT). No. of bitstreams: 1 ntu-107-R05447014-1.pdf: 5908356 bytes, checksum: 7295da811934299a902bc5cdc996b4d7 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員會審定書 i
Acknowledgements ii 中文摘要 iii Abstract v Table of Contents vii List of Figures xii List of Tables xiv Chapter 1. Introduction 1 1.1 Decitabine 1 1.1.1 History of decitabine 1 1.1.2 Mechanisms of Decitabine 1 1.1.3 Decitabine as a treatment regimen for elderly patients with acute myeloid leukemia 2 1.2 Acute Myeloid Leukemia 3 1.2.1 Characteristics and Epidemiology of Acute Myeloid Leukemia 3 1.2.2 Treatment for Acute Myeloid Leukemia 4 1.2.3 Subtypes of acute myeloid leukemia 5 1.3 Epigenetics 6 1.3.1 Definition of epigenetics and histone code regulation 6 1.3.2 Epigenetics in Acute Myeloid Leukemia 8 1.4 Kasumi-1 cell line 9 1.5 Proteomics 10 1.5.1 SILAC and shotgun proteomics for protein quantification 10 1.5.2 Proteomics in AML and decitabine studies 11 1.6 Previous research findings on methylome, transcriptome and histone modification 12 Chapter 2. Aim of Study 14 Chapter 3. Materials and Methods 16 3.1 Cell culture 16 3.2 Protein isolation for mass spectrometry analysis 16 3.3 Nuclear protein isolation for mass spectrometry analysis 17 3.4 Western Blot 19 3.5 Mass Spectrometry sample preparation 19 3.5.1 Separation of protein into fractions by using SDS-PAGE 19 3.5.2 Gel Protein staining & dividing into fractions 20 3.5.3 In-gel digestion 20 3.5.4 Peptide extraction from gel 21 3.5.5 C18 column de-salting 21 3.5.6 Liquid Chromatography – tandem mass spectrometry (LC-MS/MS) 21 3.6 Data Analysis 24 3.6.1 Peptide Identification 24 3.6.2 Proteomics data transformation 26 3.6.3 Cytoscape 27 3.6.4 DAVID: Database for Annotation, Visualization and Integrated Discovery 27 3.6.5 BiNGO : Biological Network Gene Ontology tool 28 3.6.6 STRING pathway database 28 3.6.7 MCODE clustering 29 3.6.8 GeneMania 29 3.6.9 Protein spectral validation 29 Chapter 4. Results 30 4.1 Protocol optimization for SILAC based mass-spectrometry experiment with Kasumi-1 cells 30 4.1.1 Introduction 30 4.1.2 Decitabine caused significant downregulation of DNMT1 by Day4. The level returns toward baseline after rest (Day8). 31 4.1.3 Cell culture optimization 32 4.2 Nuclear protein isolation improved identification of epigenetic proteins 33 4.3 Peptide identification and quantification 34 4.3.1 Summary of identified peptides across all data 34 4.3.2 Nuclear proteins enrichment 36 4.4 Functional Enrichment Analysis 37 4.4.1 Ontological Analysis of Total Cell Protein 38 4.4.2 Ontological analysis of nuclear proteins with protein network clustering 38 4.4.3 Ontological analysis of all Day8 data 40 4.5 Modulated epigenetic proteins by decitabine treatment 40 4.6 DNMT1 interacting proteins 41 4.7 Comparison with Methylation arrays and Expression arrays 42 4.7.1 Promoter demethylation by decitabine 42 4.7.2 Gene expression microarrays 43 4.7.3 Upregulated proteins of tumor suppressing genes 43 4.8 Protein expression validation 43 4.8.1 Peptide spectrum validation 43 4.8.2 HELLS western blot validation 44 Chapter 5. Discussion 45 5.1 Proteomics data quality and technical limitations 45 5.2 Significance of transient low-dose decitabine treatment methodology 45 5.3 Proteins that are differentially expressed by decitabine and studies by other researchers 46 5.4 DNMT1 interacting protein function and Epigenetic-protein function 47 5.5 The role of HELLS in Acute Myeloid Leukemia 47 Chapter 6. Conclusion 49 References 51 Figures 59 Tables 85 Appendix 99 Appendix 1 - list of western blot antibodies 99 Appendix 2 - Parameters for MaxQuant analysis 100 Appendix 3 - Data Processing Tools 103 Appendix 4 - Additional ontology analysis of total cell proteome with BiNGO 104 Appendix 5 - Ontological Analysis of DATA3-Day4 106 Appendix 6 - Ontological Analysis of DATA3-Day8 108 Appendix 7 - GO_Biological_Process of upregulated proteins from DATA3-Day4 110 Appendix 8 - Table of Gene Ontology annotations for Day4-Upregulated 111 Appendix 9 - GO_Biological_Process of downregulated proteins from DATA3-Day4 112 Appendix 10 - Table of Gene Ontology annotations for Day4-Downregulated 113 Appendix 11 - Hierarchically clustered Quantile Analysis of Gene Ontology for Data3-Day8 with GO_Biological_Process 114 | |
dc.language.iso | en | |
dc.title | 經低劑量地西他濱治療之急性骨髓性白血病細胞以非放射性同位素標定胺基酸細胞培養進行蛋白質體分析 | zh_TW |
dc.title | SILAC-based Proteomics Analysis on AML Cell Line with Transient Low-Dose Decitabine Treatment | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 周文堅(Wen-Chien Chou),黃泰中(Tai-Chung Huang) | |
dc.subject.keyword | 地西他濱,急性骨髓性白血病,蛋白質體學,非放射性同位素標定胺基酸細胞培養,表觀遺傳, | zh_TW |
dc.subject.keyword | Decitabine,Acute Myeloid Leukemia (AML),Proteomics,SILAC,Epigenetics, | en |
dc.relation.page | 115 | |
dc.identifier.doi | 10.6342/NTU201803391 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-08-20 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 毒理學研究所 | zh_TW |
顯示於系所單位: | 毒理學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 5.77 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。